Bicara Therapeutics Inc. AI Stock Analysis
Want to see BCAX full AI Analyst Report?
Bicara Therapeutics Inc. (BCAX) AI Stock Analysis
Bicara Therapeutics Inc.
(NASDAQ:BCAX)
The score is held down primarily by weak financial performance (pre-revenue with accelerating losses and cash burn) and bearish technicals (price below all key moving averages with negative MACD). These are partially offset by a constructive earnings-call outlook (pivotal trial progress, Breakthrough Therapy designation, and cash runway into 1H 2029), while valuation inputs are limited due to negative earnings and no dividend yield data.
Bicara Therapeutics Inc. (BCAX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $647.28M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.17M
- Price to Earnings (P/E)
- -2.8
- Beta (1Y)
- 1.71
- Revenue Growth
- ―
- EPS Growth
- -55.27%
- Country
- US
- Employees
- 103
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Bicara Therapeutics Inc. Business Overview & Revenue Model
Company Description
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors...
How the Company Makes Money
As a clinical-stage biotechnology company, Bicara Therapeutics’ primary economic activity is advancing drug candidates through discovery, preclinical development, and clinical trials rather than generating recurring revenue from product sales. Detail...
Bicara Therapeutics Inc. Earnings Call Summary
The call was predominantly positive, driven by substantial pivotal-trial enrollment, plans for an interim overall survival analysis, encouraging and durable Phase Ib efficacy data, Breakthrough Therapy designation, commercial preparation, and a cash runway into the first half of 2029. The main negatives were sharply higher operating expenses, the absence of pivotal data to date, pending regulatory clarity, a competitive market, and the still-early, late-line status of the colorectal cancer program.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Bicara expects top line interim analysis from FORTIFI-HN01 in the middle of next year and plans to incorporate an interim overall survival analysis, although it has not guided to when that will occur; the study is around 650 patients and the company does not expect to need to upsize it. CRC data are planned for presentation in January, FORTIFI-FLEX data are anticipated prior to the first approval, and its overall design remains unchanged. The company anticipates that overall operating expenses through year-end will remain consistent with its most recent quarterly results, while approximately $442.3 million in cash, cash equivalents and marketable securities provides cash runway into the first half of 2029. Bicara continues to view timing as less than a year between itself and petosemtamab.
Bicara Therapeutics Inc. Financial Statement Overview
Summary
Financial profile is pressured by being pre-revenue with rapidly widening losses and accelerating cash burn (TTM net loss about -$220.3M; operating cash flow about -$161.7M; FCF about -$162.8M), increasing financing/dilution risk. Offsetting this, leverage is minimal (about $0.9M debt vs. $409.4M equity) and the asset/equity base is sizeable, providing some balance-sheet flexibility despite deteriorating ROE (about -49.1% TTM).
Income Statement
12Very NegativeBalance Sheet
74PositiveCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -219.87M | -137.63M | -67.75M | -51.96M | -37.72M |
| Net Income | -220.28M | -137.95M | -68.00M | -51.98M | -37.84M |
Balance Sheet | |||||
| Total Assets | 460.64M | 430.99M | 510.00M | 233.98M | 6.70M |
| Cash, Cash Equivalents and Short-Term Investments | 442.35M | 414.80M | 489.71M | 230.44M | 4.16M |
| Total Debt | 880.00K | 1.71M | 738.00K | 657.00K | 0 |
| Total Liabilities | 51.23M | 29.54M | 18.12M | 15.47M | 23.98M |
| Stockholders Equity | 409.41M | 401.45M | 491.88M | 218.51M | -17.28M |
Cash Flow | |||||
| Free Cash Flow | -162.75M | -107.11M | -74.82M | -46.21M | -32.27M |
| Operating Cash Flow | -161.73M | -106.83M | -74.75M | -45.63M | -32.08M |
| Investing Cash Flow | -128.04M | -318.45M | -9,000 | -586.00K | -192.00K |
| Financing Cash Flow | 200.12M | 32.26M | 334.03M | 272.50M | 31.70M |
Bicara Therapeutics Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCAX, the sentiment is Negative. The current price of 9.75 is below the 20-day moving average (MA) of 11.86, below the 50-day MA of 16.57, and below the 200-day MA of 20.80, indicating a bearish trend. The MACD of -2.14 indicates Negative momentum. The RSI at 33.17 is Neutral, neither overbought nor oversold. The STOCH value of 57.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCAX.
Bicara Therapeutics Inc. Risk Analysis
Bicara Therapeutics Inc. disclosed 83 risk factors in its most recent earnings report. Bicara Therapeutics Inc. reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskBicara Therapeutics Inc. Peers Comparison
Overall Rating
SRPT58Neutral
TSHA54Neutral
NTLA49Neutral
BCAX49Neutral
WVE47Neutral
STOK46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 58Neutral | $1.62B | 168.58 | 1.04% | ― | -18.95% | 59.85% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 54Neutral | $1.32B | -9.46 | -51.87% | ― | -13.07% | -23.02% | |
| 49Neutral | $1.38B | -2.91 | -64.73% | ― | -8.07% | 21.55% | |
| 49Neutral | $647.28M | -2.76 | -49.13% | ― | ― | -55.27% | |
| 47Neutral | $566.05M | -2.69 | -44.48% | ― | -35.07% | -45.17% | |
| 46Neutral | $1.74B | -7.01 | -67.30% | ― | -86.28% | -634.38% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BCAX | Bicara Therapeutics Inc. | 9.75 | -5.43 | -35.77% | |
| SRPT | Sarepta Therapeutics Inc. | 15.13 | -1.26 | -7.69% | |
| WVE | Wave Life Sciences Pte. Ltd | 2.87 | -4.01 | -58.28% | |
| NTLA | Intellia Therapeutics Inc | 9.86 | 1.62 | 19.66% | |
| STOK | Stoke Therapeutics | 26.63 | -1.85 | -6.50% | |
| TSHA | Taysha Gene Therapies, Inc. | 4.06 | 0.05 | 1.25% |
Bicara Therapeutics Inc. Corporate Events
Bicara Therapeutics Secures Boston Headquarters Through Sublease
PositiveOn August 21, 2026, Bicara Therapeutics Inc. entered into a sub-sublease agreement with Wayfair LLC to secure approximately 35,090 square feet of office space at 10 St. James Avenue in Boston for its new corporate headquarters. The lease term will co...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 10, 2026
